Lys168
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.1.1
Powered by Cell Signaling Technology
Home > Acetylation Site Page: > Lys168  -  TPM2 (human)

Site Information
kyEEVARkLVILEGE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 27585249
Available spectra:  2 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 )
Disease tissue studied:
gastric cancer ( 2 ) , lung cancer ( 1 ) , non-small cell lung cancer ( 1 , 3 ) , non-small cell squamous cell lung carcinoma ( 3 )
Relevant cell line - cell type - tissue:
Calu-3 (pulmonary) ( 1 ) , HCC827 (pulmonary) ( 1 ) , lung ( 1 ) , MKN-45 (gastric) ( 2 ) , NCI-H1650 (pulmonary) ( 1 ) , NCI-H1703 (squamous) ( 3 ) , NCI-H1975 (pulmonary) ( 1 ) , NCI-H2106 (pulmonary) ( 1 )

References 

1

Rikova K (2013) CST Curation Set: 20217; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

2

Rikova K (2012) CST Curation Set: 16030; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

3

Rikova K (2012) CST Curation Set: 16032; Year: 2012; Biosample/Treatment: cell line, H1703/gleevec; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.